FDA rejects Regeneron lymphoma drug, setting back company’s oncology push
Bio Pharma Dive
MARCH 25, 2024
The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers.
Let's personalize your content